Ascertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugs.
Serious adverse reactions during malaria chemoprophylaxis are reviewed. Three drugs considered to have caused serious reactions in recent years are pyrimethamine/sulfadoxine (Fansidar), pyrimethamine/dapsone (Maloprim) and amodiaquine. These reactions are principally independent of dose and cannot be determined during screening for optimal doses. However, host factors may precipitate dose-dependent reactions, some of which could be avoided with improvements in drug licensing. Since serious and life-threatening reactions are relatively rare (between 1:1000 and 1:20,000), Phase I to III trials cannot identify them. Reliance must therefore be placed on Phase IV post-marketing studies, including ongoing reviews of national registers, and specially tailored studies to identify the risk using prescription-event monitoring in high-risk populations. Occasionally, medical-record linkage, case-control and cohort studies may provide supportive data. Although large numbers of travellers must, of necessity, be exposed to a drug before relatively rare reactions are identified, the ascertainment of risk using post-marketing surveillance was prevented by the following five deficiencies: lack of awareness of early alerts, inadequate use of national registers, poor attention to epidemiological and statistical rigour, inadequate verification of denominators, and inadequacy of data records. Recommendations are given for minimizing such errors in the future.
Department of Epidemiology and Population Sciences, London School of Hygiene and Tropical Medicine, England.
P A
PA
Phillips-Howard
A B
AB
Bjorkman
D000655:Amodiaquine / Q000009:adverse effects; D000962:Antimalarials / Q000009:adverse effects*; D002986:Clinical Trials as Topic / Q000592:standards; D003622:Dapsone / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D006801:Humans; D011358:Product Surveillance, Postmarketing; D011739:Pyrimethamine / Q000009:adverse effects; D013413:Sulfadoxine / Q000009:adverse effects
D000962:Antimalarials; D004338:Drug Combinations; D000655:Amodiaquine; C001205:fanasil, pyrimethamine drug combination; C001678:Maloprim; D013413:Sulfadoxine; D003622:Dapsone; D011739:Pyrimethamine